GSK unveils restructuring plans in France after merger
GlaxoSmithKline is undertaking substantial restructuring in France inthe wake of the December merger of Glaxo Wellcome and SmithKline Beecham. A document circulated to workforce representatives indicates that the former headquarters of SB at Nanterre is to be closed, while the HQ of the new company in France will be sited at the former GW site at Marly-le-Roi.
GSK's R&D activities will be regrouped in a single centre at Ulis, and the former SB research center at Rennes will be closed. In all, 162 jobs will be lost, with 48 members of staff being transferred to other sites, according to the document. Meanwhile, a total of 192 new jobs will be created.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze